Recent patents on live bacteria and their products as potential anticancer agents

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 1, 2012, Pages 31-55

  Fialho, Arsenio M ^a   Bernardes, Nuno ^a   Chakrabarty, Ananda M ^b  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Anticancer drugs; Bacteria; Bacterial products; Cancer; Patents

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE DEIMINASE; ASPARAGINASE; AZURIN; BACTERIAL VACCINE; BCG VACCINE; BOTULINUM TOXIN; CLAUDIN; CLOSTRIDIUM TOXIN; CUPREDOXIN; CYPHER; CYTOTOXIC AGENT; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; DNA VACCINE; ELLIPTICINE; ELLIPTICINE DERIVATIVE; EXOENZYME C3; FLUCYTOSINE; GLUTADON; IMMUNOTOXIN; LISTERIOLYSIN; LISTERIOLYSIN S; LIVE VACCINE; METHIONINE GAMMA LYASE; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RAPAMYCIN; SHIGA TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BACTERIAL STRAIN; BIFIDOBACTERIUM; BONE CANCER; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM PERFRINGENS; COLON CANCER; DNA MODIFICATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYBRID CELL; IMMUNOMODULATION; LISTERIA MONOCYTOGENES; METASTASIS; MICROBIAL ATTENUATION; MYCOBACTERIUM TUBERCULOSIS; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PATENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; UTERINE CERVIX CANCER; UTERUS CANCER;

EID: 83455233893     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212798357949     Document Type: Review

References (131)

1. Fialho AM, Chakrabarty AM. Recent patents on bacterial proteins as potential anticancer agents. Recent Pat Anticancer Drug Discov 2007; 2: 224-34.
2. Coley WB. Contribution to the knowledge of sarcoma. Ann Surg 1891; 14: 199-220.
3. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci 1893; 105: 487-511.
4. Coley WB. The idea of progress. Trans NY N Engl Assoc Railway Surg 1920: 6.
5. Fialho AM, Chakrabarty AM. Emerging Cancer Therapy: Microbial approaches and Biotechnological Tools. 1st ed. Wiley & Sons: New York, 2010.
6. Eisenstark, A., Kazmierczak, R. Microorganism strain CRC2631 of Salmonella typhimurium and its use as a cancer therapeutic. US20100135973 (2010).
7. Luo, Y., Xiang, R. DNA vaccines against tumor growth and methods of use thereof. US20100136058 (2010).
8. Leonard, A., Saltzman, D.A. Method of cancer treatment. US2010098665 (2010).
9. Bereta, M., Paulina, C. New strain of Salmonella enteric, S. typhimurium, its use and a method to obtain a therapeutic vaccine vector. WO2010095966 (2010).
10. Saltzman D.A, Leonard A., Mueller M.J. Method of cancer treatment. CA2701052 (2010).
11. Sprott, G.D., Krishnan, L., Sad, S. Vaccine adjuvant properties of liposomes formed at elevated temperatures from the polar chloroform extractable lipids from Mycobacterium bovis. US20080248094 (2008).
12. Garcia, U.P Process for obtaining a product containing polar lipids and mycobacterial hydrophilic substances from Mycobacterium tuberculosis used as a vaccine or immunostimulant. MX2008001575 (2009).
13. Wagner, T.E., Wei, Y. Combination therapy of hybrid cells with BCG injection for treating cancer patients. US2009087450 (2009).
14. Marchal, G., Abolhassani, M. Recombinant Mycobacterium strain expressing a mycobacterial FAP protein under the control of a promoter active under hypoxia and its application for cancer therapy. HK1112753 (2010).
15. Jo, E.K., Kim, K.K., Shin, D.M, Lee, H.M. Pharmaceutical composition containing Mycobacterium tuberculosis-EIS recombinant protein as an active ingredient. KR20100119161 (2010).
16. Santin, A.D. Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer. US20090291047 (2009).
17. Mckerracher, L., Lasko, D. Clostridium botulinum C3 exotransferase compositions and methods for treating tumour spreading. US20090285833 (2009).
18. Nakanishi, T. Growth inhibitor of colon cancer cells. JP2009269836 (2009).
19. Woo, S.L.C, Li, Z. Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic therapy. WO2009111177 (2009).
20. Yunlong, C., Hongfu, L. Use of Clostridium butyricum in preparing medicine composition for preventing and curing intestinal cancer. CN101306020 (2008).
21. Paterson, Y. Specific immunotherapy of cancer using live recombinant bacterial vaccine vector. JP2007254485 (2007).
22. Maciag, P., Wallecha, A., Shahabi, V. Dual delivery system for heterologous antigens. WO2009143167 (2009).
23. Paterson, Y., Rothman, J. Compositions and methods for treatment of cervical cancer. US2009081250 (2009).
24. Lenz, L.L., Schmidt, R.L. Compositions, methods and uses for stimulating immune responses. WO2011060093 (2011).
25. Shahabi, V., Seavey, M., Paterson, Y. Live Listeria-based vaccines for central nervous system therapy. WO2011100754 (2011).
26. Kim, D.H., Kim, S.W. Fermented fruit and anti-cancer pharmaceutical composition containing the same. KR20070024447 (2007).
27. Sukumar, S.V., Kominsky, S.L. Claudins as markers for early detection, diagnosis, prognosis and as targets of therapy for breast and metastatic brain or bone cancer. US20090155278 (2009).
28. Santin, A.D. Antineoplastics activities of ellipticine and its derivatives. WO2007102869 (2007).
29. Yagi, K., Kondoh, M., Isoda, k., Horiguchi, Y. Mucosal vaccine. WO2010089940 (2010).
30. La Monica, N., Scarselli, E., Ciliberto, G., Aurisicchio, L., Fridman, A., Bagchi, A. Minigene. US20110182926 (2011).
31. Hochberg, A. Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer. US20090221681 (2009).
32. Harrison, R.J., Vanderspek, J.C. Diphtheria toxin variant. US20090156502 (2009).
33. Mekata, E., Miyamoto, S. Anticancer agent. JP2008285491 (2008).
34. Leppla, S.H., Avallone, J., Bugge, T., Liu, Shi-Hui, Osorio, M. Activation of recombinant Diphtheria Toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells. US20080166375 (2008).
35. Frankel, A.E. Methods and compositions based on diphtheria toxininterleukin-3 conjugates. CA2698595 (2008).
36. Dimofilos, N.C. Endoprostatic srping (Stent) impregnated with Rapamycin/Sirolimus and Shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract. GR1006552 (2009).
37. Kovbasnjuk, O.N., Donowitz, M. Treatment of metastatic colon cancer with b-subunit of shiga toxin. US2007071772 (2007).
38. Goud, B., Johannes, L. Chimeric polypeptide comprising fragment b of Shiga toxin and peptide of therapeutic interest. JP2010180216 (2010).
39. Johannes, L., Grierson, D., Robine, S., Florent, J-C., Maillard, P., Roger, J. Shiga Toxin b-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors. US20100329992 (2010).
40. Johannes, L., El Alaoui, A., Decaudin, D., Robine, S., Schmidt, F., Florent J-C. Shiga toxin b-subunit/chemotherapeutics conjugates. US20110152252 (2011).
41. Shaari, C. Treating neoplasms with neurotoxin. US20100209456 (2010).
42. Chancellor, M.B., Fraser, M.O., Chuang, Yao-Chi, De Groat, W.C., Huang L., Yoshimura N. Application of lipid vehicles and use for drug delivery. US2007003610 (2007).
43. Gallez, B., Ansiaux, R. Methods and compositions for the treatment of cancer. US20090232849 (2009).
44. Stephen, B.M.F.D. Methods for treating cancers. CN101031317 (2007).
45. Pastan, I.H., Ho, M., Bang, S.-H. Pseudomonas exotoxin A mutants and uses thereof. EP2204385 (2010).
46. Yarkoni, S., Nechushtan, A., Lorberboum-Galski, H., Marianovsky, I. Chimeric toxins for targeted therapy. US20090181894 (2009).
47. Zangemeister-Wittke U., De Paolo, C. Methods for treating cancer using an immune-toxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer associated protease site cleaved by MMP-2 or MMP-9. US20090214543 (2009).
48. Winkles, J., Brown, S. Tweak-pseudomonas exotoxin a fusion protein for cancer therapy. US20080175896 (2008).
49. Fey, G.H., Peipp, M. Schwemmlein, M. CD19-specific immunotoxin and treatment method. WO2007085470 (2007).
50. Paterson, Y. Specific immunotherapy of cancer using live recombinant bacterial vaccine vector. JP2007254485 (2007).
51. Ross, P., Hill, C., Cotter, P. Listeria monocytogenes cytotoxin Listeriolysin S. IE20080050 (2009).
52. Ensor, C.M., Holtsberg, F.W., Clark, M.A. Mutated form of arginine deiminase. PT1278868 (2008).
53. De Simone, C. Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria. SI1058725 (2008).
54. Sun, Z., Zheng, P., Ni, Ye., Liu, Y., Liu, Y. A strain capable of producing arginine deiminase and the use thereof. WO2008141523 (2008).
55. Gruber, H.E., Jolly, D., Olmstead, K. Formulations of 5- fluorocytosine and uses thereof. WO2010002937 (2010).
56. Cady, C., Mcasey, M. Stem cell targeting of cancer, methods and compositions therefor. WO2009052394 (2009).
57. Buchsbaum, D.J., Gillespie, G.Y., Markert, J.J.M., Kaliberov, S.A. Viral vector driven mutant bacterial cytosine deaminase gene and uses thereof. US20070225245 (2007).
58. Harrison, R.G., Pento, J.T., Lind, S. Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof. US20090304666 (2009).
59. Bausch, M. Wetzler, R., Mueller, C. Glutadon. US20090169537 (2009).
60. Roberts, J., Macallister, T.W., Sethuramen, N., Freeman, A.G. Genetically engineered glutaminase and its use in antiviral and anticancer therapy. EP1854876 (2007).
61. Dufour, E.-C., Godfrin, Y. Medicament for the treatment of cancer of the pancreas. WO2009080837 (2009).
62. Fyfe, G., Holmgren, E., Mass, R.D., Novotny, W. Treatment with anti-VEGF antibody. JP2007326860 (2007).
63. Zhou, T., Ichikawa, K., Kimberly, R.P., Koopman, W.J., Oshumi, J., Lobuglio, A.F., Buchsbaum, D.J. Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents. NZ533164 (2008).
64. Abribat, T. Pegylated L-asparaginase. WO2011003886 (2011).
65. Das Gupta, T., Chakrabarty, A.M., Fialho, A. Compositions and methods to prevent and/or treat cancer with Pa-CARD. WO2010096754 (2010).
66. Taylor, B., Metha, R., Yamada, T., Beattie, C., Das Gupta, T. Compositions and methods to prevent cancer with cupredoxins. WO2010080506 (2010).
67. Das Gupta, T., Metha, R., Metha, R., Beattie, C. Compositions and methods to prevent cancer with cupredoxins. WO2010078042 (2010).
68. Das Gupta, T., Chakrabarty, A. Compositions and methods to prevent cancer with cupredoxins. US2010087377 (2010).
69. Beattie, C., Yamada, T., Das Gupta, T. Compositions and methods to prevent cancer by stabilizing p53 through non MDM2-mediated pathways. US2010093057 (2010).
70. Chakrabarty, A., Das Gupta, T. Compositions and methods to treat cancer with cupredoxins and CpG rich DNA. MX2009005849 (2009).
71. Chakrabarty, A., Das Gupta, T., Yamada, T., Chaudhari, A., Fialho, A., Zhu, Y. Compositions and Methods for treating conditions related to ephrin signaling with cupredoxins. US20080312413 (2008).
72. Das Gupta, T., Chakrabarty, A., Punj, V., Zaborina, O. Cytotoxic factor for modeling cell death. JP2009091370 (2009).
73. Taylor, B., Metha, R., Yamada, T., Beattie, C., Das Gupta, T. Compositions and methods to prevent cancer with cupredoxins. WO2010080506 (2010).
74. Das Gupta, T., Metha, R., Metha, R., Beattie, C. Compositions and methods to prevent cancer with cupredoxins. WO2010078042 (2010).
75. Das Gupta, T., Chakrabarty, A. Compositions and Methods to Prevent Cancer with Cupredoxins. US2010087377 (2010).
76. Beattie, C., Yamada, T., Das Gupta, T. Compositions and methods to prevent cancer by stabilizing p53 through non MDM2-mediated pathways. US2010093057 (2010).
77. Fujiya, M., Kohgo, Y., Okamoto, K. Anti-tumor agent for gastrointestinal cancer. WO2009093447 (2009).
78. Coquin, L., Jourdan, F., Pierrat, O., Lowe, D.J., Maxwell, A., Pickett, C.J., Wall, M. Microcin B17 analogs and methods for their preparation and use. US2008234132 (2008).
79. Choi, C.H., ham Gyeong, S., lee Dong, G. Peptide with enlarged hydrophobic domain by substituting hydrophilic domain of pep-27 peptide with other amino acids, and pharmaceutical composition containing the same. KR20030073833 (2003).
80. Packhman, G.K., Ganesan, A., Cecil, A.R.L. Depsipeptides and their therapeutic use. US2010056434 (2010).
81. Shuttleworth, S.J., Silva, F.A., Tomassi, C.D., Cecil, A.R.L., Hill, T.J. Spiruchostatin derivatives and their therapeutic use. GB2460181 (2009).
82. Shuttleworth, S.J., Silva, F.A., Tomassi, C.D., Cecil, A.R.L., Hill, T.J. Spiruchostatin analogues and their therapeutic use. GB2460180 (2009).
83. Shuttleworth, S.J., Silva, F.A., Tomassi, C.D., Cecil, A.R.L., Ganesan, A., Hill, T.J. Spiruchostatin derivatives and their therapeutic use. GB2460178 (2009).
84. Toyooka, T., Ibuki, Y. Method for killing tumor by photosensitization treatment under conditions where histone is highly acetylated. WO2010064422 (2010).
85. Vrolijk, N.H., Verdine, G.L. Romidepsin-based treatments for cancer. US2010093610 (2010).
86. Keegan, M., Grant, S. Combination therapy comprising romidepsin and I.A. bortezomib. MX2009007777 (2009).
87. Mcculloch, W., Keegan, M. Treatment of Ras-expressing tumors. US20090305956 (2009).
88. Frenkel, E.P. Combination therapy for cancer. WO2008127659 (2008).
89. Mengfeng, L., Jie, Y., Birun, L., Xun, Z., Jiahui, P., Yongcheng, L., Jueheng, W., Li, J., Zhenjian, H., Minghui, G. Application of actinomycin compound actinomycin V in preparing drugs for anti liver cancer. CN101601856 (2009).
90. Qinglun, K. Novel anticancer sustained-release injection. CN101427996 (2009).
91. Yang, B.S., Cho, S.J. The inhibitor on the binding of DDR proteins to collagens comprising an actinomycin D as an effective compound. KR20090042398 (2009).
92. Qingzhong, K., Jie, Z. Temperature controlled sustained-release injection containing anti-cancer medicine. CN101273965 (2008).
93. Kim, J.S. Temperature-sensitive immunoliposomes, preparation method and uses thereof. KR20080000007 (2008).
94. Kin, S.Y., Park, K.S., Jeong, K.C. A cancer sensitizer comprising chlorogenic acid. KR20090033699 (2009).
95. Kim, S.Y., kim, D.S. A cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof. KR20070120015 (2007).
96. Trachsel, E., Kaspar, M., Neri, D., Marlind, J. Immunocytokines for cancer treatment in combination with chemotherapeutic agents. US20100215615 (2010).
97. Martell, R.A., Karlin, D.A., Breitz, H.B., Weiden, P.L. Combination therapy for ovarian cancer. US20100178328 (2010).
98. Shin, D.-Y., Kim, J.-S. Anti-cancer medicine both for diagnosing and treating cancer. US20100158812 (2010).
99. Joshi, K., Rathos, M., Sharma, S, Khanwalkar, H. A synergistic pharmaceutical combination for the treatment of cancer. MX2009012155 (2010).
100. Estok, T.M., Zaknoen, S., Baum, C.M. Methods of treating ovarian cancer. US20100112039 (2010).
101. Chandrasekher, Y.A., Mckernan, P.A. Method for treating cervical cancer. JP2010013467 (2010).
102. Liu, Y., Shen, Y., Yang, T., Wang, J. Use of lymphotoxin for sensitizing tumor cells to chemotherapeutic drugs. WO2009062344 (2009).
103. Granada, F., Furnish, S.M. Apparatus and method for delivery of Mitomycin through an eluting biocompatible implantable medical device. US20080161908 (2008).
104. Qiqing, Z., Qian, W., Yange, W., Zhenqing, H., Shefang, Y. Mitomycin double sustained release film of implanted antineoplastic agents and its preparation method. CN101204382 (2008).
105. Li, Y., Peterson, C., Rudge, S.R., Stevens, S., Tapolky, G.H. Magnetically targetable Mitomycin C compositions and methods of their use. US20070274907 (2007).
106. Scherlach, K., Partida-Martinez, L., Hertweck, C. Antimitotic Rhizoxin deritivatives of Burkholderia rhizoxina, method for producing said derivatives and use thereof. US20090233976 (2009).
107. Hertweck, C., Partida-Martinez, L.P. Burkholderia rhizoxina micro- organisms, novel endosymbionts of rhizopus sp. and method for producing rhizoxin and/or rhizoxin-derivates using said microorganisms. US20090209013 (2009).
108. Schuler, M. Staurosporine derivatives for treating non-small cell lung cancer. KR20080046161 (2008).
109. Wilkinson, B., Moss, S. Zhang, M. Novel compounds. US20090312316 (2009).
110. Rothermel, J.D. Epothilone derivative for the treatment of hepatoma and other cancer diseases. HK1073601 (2010).
111. Zaknoen, S., Woo, M.M., Versace, R.W., Pisano, C., Vesci, L. Combinations of therapeutic agents for treating cancer. NZ555370 (2010).
112. Juan, S., Yuyan, L., Qingxin, K. Anti-cancer sustained-released injection containing epothilone derivate. CN101396340 (2009).
113. Dilea, C., Mcsheey, P.M.J., Maira, S.-M., Tanaka, C., Wartmann, M. Cancer treatment with epothilones. US2009069394 (2009).
114. Rothermel, J.D. Epothilone derivative for the treatment of hepatoma and other cancer diseases. US20080161369 (2008).
115. Palmer, P.A., Horak, I.D. Farnesyl protein transferase inhibitors for treating breast cancer. US2009018164 (2009).
116. Rose, S.D., Lefler, S.R., Ottersberg, S.R., Kim, A.Y., Okolotowicz, K.J., Hartman, R.F. Anticancer agents based on regulation of protein prenylation. US20090143467 (2009).
117. Wang, J. J-S., Cooper, A., Zhu, H., Desai, J. Novel farnesyl protein transferase inhibitors as antitumor agents. MX2007007611 (2009).
118. Kelly, J.M., Afonso, A. Farnesyl protein transferase inhibitors. US20070213340 (2007).
119. Rane, D. Novel farnesyl protein transferase inhibitors and their use to treat cancer. MX2007007074 (2007).
120. Palladino, M., Neuteboom, S.T.C., Macherla, V.R.R., Potts, B.C. Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases. NZ544588 (2010).
121. Macherla, V.R.R., Potts, B.C., Manan, R.R., Mcarthur, K.A., Chao, T., Neuteboom, S.T.C. Salinosporamide derivatives as proteasome inhibitors. WO2009140287 (2009).
122. Myers, A.G., Sun, B., Jackson, S.R. Analogs of salinosporamide A. US2009054665 (2009).
123. Bonavida, B., Palladino, M. Methods of sensitizing cancer to therapy- induced cytotoxicity. WO2007056335 (2007).
124. Lam, k.S., Palladino, M. Biosynthesis of salinosporamide A and its analogs. WO2007030662 (2007).
125. Romo, D., Cho, S.W., Smith, J.W., Richardson, R.D. Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis. WO2008006113 (2008).
126. Kaiser, M., Clerc, J. Derivatives of syringolin A. EP2210881 (2010).
127. Kaiser, M., Clerc, J. Development of a synthesis of syringolin A and B and derivatives thereof. US2010022767 (2010).
128. Desai, N.P., Soon-Shiong, P., Trieu, V. Nanoparticle comprising rapamycin and albumin as anticancer agent. US20100183728 (2010).
129. Hung, H.T. Chee, S.K. Composition of mTOR antagonist and angiogenesis inhibitor for treating cancer. CN101583357 (2009).
130. Sun, C.L. Li, X. Rapamycin analogs as anti-cancer agents. WO2009131631 (2009).
131. Y.C.A.S., Hernandez, L.J., Jimeno, D.J.M. Raymond, E. Improved antitumoral treatments. WO2009109649 (2009).